» Articles » PMID: 15496626

Therapeutic Potential of RNA Interference

Overview
Journal N Engl J Med
Specialty General Medicine
Date 2004 Oct 22
PMID 15496626
Citations 42
Authors
Affiliations
Soon will be listed here.
Citing Articles

Therapeutic Effects of WT1 Silencing via Respiratory Administration of Neutral DOPC Liposomal-siRNA in a Lung Metastasis Melanoma Murine Model.

Ramos-Gonzalez M, Vazquez-Garza E, Garcia-Rivas G, Rodriguez-Aguayo C, Chavez-Reyes A Noncoding RNA. 2023; 9(2).

PMID: 36960966 PMC: 10037624. DOI: 10.3390/ncrna9020021.


A supramolecular platform for controlling and optimizing molecular architectures of siRNA targeted delivery vehicles.

Wen Y, Bai H, Zhu J, Song X, Tang G, Li J Sci Adv. 2020; 6(31):eabc2148.

PMID: 32832695 PMC: 7439508. DOI: 10.1126/sciadv.abc2148.


Novel strategy for a bispecific antibody: induction of dual target internalization and degradation.

Lee J, Lee S, Hwang J, Oh S, Kim B, Jung S Oncogene. 2016; 35(34):4437-46.

PMID: 26853467 DOI: 10.1038/onc.2015.514.


Simultaneous gene silencing of KRAS and anti-apoptotic genes as a multitarget therapy.

Werner K, Lademann F, Thepkaysone M, Jahnke B, Aust D, Kahlert C Oncotarget. 2015; 7(4):3984-92.

PMID: 26716649 PMC: 4826184. DOI: 10.18632/oncotarget.6766.


Time depended Bcl-2 inhibition might be useful for a targeted drug therapy.

Talaiezadeh A, Jalali F, Galehdari H, Khodadadi A Cancer Cell Int. 2015; 15:105.

PMID: 26535028 PMC: 4630962. DOI: 10.1186/s12935-015-0254-5.